The Scandinavian health network. Connecting the Scandinavian countries' health networks
The Scandinavian countries are all among the minority of the world's nations that have established a national health network infrastructure. These networks provide a secured communication environment for health professionals, mainly in hospitals and local health services/GPs. Despite serving similar requirements, these national infrastructures differ in several aspects: organizational extension, choice of carrier technology, IP addressing and NAT strategy, DNS implementation and QoS support. Initiatives to interconnect these national health networks in Scandinavia date several years back, and today the Danish health network has a number of cross-border connections, including VPN tunnels to the Swedish and Norwegian health networks. However, limitations in the connecting technology, and scalability issues related to technological architecture, pose limitations on the cross-border service provisioning. The thesis investigates the differences in technical infrastructure, discusses consequences of these differences, and suggests modifications to harmonize the technology among the national health networks involved. Some of these suggestions may even have merit within national borders, as they can be seen to address scaling issues in intranetworking in general.
PublisherUniversitetet i Tromsø
University of Tromsø
The following license file are associated with this item:
Showing items related by title, author, creator and subject.
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis Norum, Jan; Antonsen, Margaret Aarag; Tollåli, Geir; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin-Helene; Helbekkmo, Nina (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-29)1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients ...
The Use of eHealth and Provider-Based Health Services by Patients with Diabetes Mellitus: Protocol for a Cross-Sectional Study Hansen, Anne Helen; Bradway, Meghan; Brož, Jan; Claudi, Tor; Henriksen, Øystein; Wangberg, Silje C; Årsand, Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-31)<b>Background:</b> The prevalence of diabetes and the use of electronic health (eHealth) resources are increasing. People with diabetes need frequent monitoring and follow-up of health parameters, and eHealth services can be of great significance in this regard. However, little is known about the extent to which different kinds of eHealth tools are used, and how the use of eHealth is associated ...
Cochrane Collaboration Systematic Reviews may be based on trials not approved by a research ethics committee Jokstad, Asbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-10-27)Systematic reviews (SR) may potentially contain reports of primary trials with ethical problems. The Cochrane Collaboration SRs are considered as the highest standard in evidence-based health care resources. All SRs completed during the last 5 years (2013–2017) under the management of the Oral Health Group of the Cochrane Collaboration were identified. All primary trials included in the Oral Health ...